EIKN Financials

Income Statement
MetricQ1 2026
Revenue
—
Cost of Revenue
0
Gross Profit
—
Operating Expenses
87.3M
R&D
70.0M
SG&A
17.3M
Operating Income
-87338000
EBITDA
-82124000
Net Income
-82958000
EPS (Basic)
$-2.46
EPS (Diluted)
$-2.46
Shares (Diluted)
33.7M
MarketsMoversWatchlist
Eikon Therapeutics (EIKN) — Financials